Mid-stage data on Allena's hyperoxaluria drug fuel optimism ahead of pivotal readout
Ahead of the pivotal data of its lead experimental drug for hyperoxaluria, Allena Pharmaceuticals revealed interim data from a small mid-stage study on Wednesday, that signaled the drug confers benefits in certain patients with advanced chronic kidney disease (CKD) that are at risk of systemic oxalosis, a potentially life-threatening condition.
Hyperoxaluria occurs due to high levels of oxalate — a natural chemical — in urine. Oxalosis occurs after the kidneys fail in individuals who have primary and intestinal causes of hyperoxaluria, and excess oxalate builds up in the blood. This can lead to oxalate deposits in blood vessels, bones and body organs, according to the Mayo Clinic.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.